Logo

Regeneron Initiates its First Clinical Study of Antibody Cocktail for the Treatment and Prevention of COVID-19

Share this

Regeneron Initiates its First Clinical Study of Antibody Cocktail for the Treatment and Prevention of COVID-19

Shots:

  • The company has reported the initiation of the first clinical trial of REGN-COV2. The REGN-COV2 clinical program will consist of four separate study populations: hospitalized COVID-19 patients- non-hospitalized symptomatic COVID-19 patients- uninfected people that are at high risk of exposure and uninfected people with close exposure to a COVID-19 patient
  • The first two adaptive P-I/II/III studies are evaluating REGN-COV2 (REGN10933+REGN10987) as a treatment for hospitalized & non-hospitalized patients with COVID-19. The P-I & P-II portion will focus on virologic and safety endpoints & clinical endpoints respectively
  • Data from the P-I/II studies will be used to refine the EPs and will determine the size for P-III studies while BARDA has funded the REGN-COV2's preclinical development and pre/clinical manufacturing. Additionally- Regeneron has developed REGN-EB3- a novel triple antibody treatment for Ebola which is under FDA’s regulatory review

Click here to read full press release/ article | Ref: Regeneron | Image: Regeneron

Related News: Regeneron to Initiate COVID-19 Antibody Program in Early Summer


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions